1. Home
  2. RDCM vs MDWD Comparison

RDCM vs MDWD Comparison

Compare RDCM & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radcom Ltd.

RDCM

Radcom Ltd.

HOLD

Current Price

$13.41

Market Cap

215.2M

Sector

Technology

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.77

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDCM
MDWD
Founded
1985
2000
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer peripheral equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
215.2M
238.5M
IPO Year
1997
2014

Fundamental Metrics

Financial Performance
Metric
RDCM
MDWD
Price
$13.41
$18.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$18.00
$37.50
AVG Volume (30 Days)
76.8K
93.0K
Earning Date
11-12-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
37.57
N/A
EPS
0.64
N/A
Revenue
$68,901,000.00
$20,932,000.00
Revenue This Year
$18.86
$15.89
Revenue Next Year
$11.39
$25.33
P/E Ratio
$20.99
N/A
Revenue Growth
17.27
6.15
52 Week Low
$9.88
$14.14
52 Week High
$15.98
$22.51

Technical Indicators

Market Signals
Indicator
RDCM
MDWD
Relative Strength Index (RSI) 55.74 55.76
Support Level $12.81 $18.55
Resistance Level $13.88 $19.05
Average True Range (ATR) 0.41 0.57
MACD 0.02 0.06
Stochastic Oscillator 62.06 66.25

Price Performance

Historical Comparison
RDCM
MDWD

About RDCM Radcom Ltd.

Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: